









ORIGINAL ARTICLE

OPEN

Missense variants in the TRPM7 α -kinase domain are associated with recurrent pediatric acute liver failure

Lea D. Schlieben^{1,2}  | Melanie T. Achleitner³ | Billy Bourke⁴ | Max Diesner⁵ | René G. Feichtinger³  | Alexander Fichtner⁶ | Christa Flechtenmacher⁷ | Nedim Hadzic⁸ | Robert Hegarty⁸  | Andreas Heilos^{9,10} | Andreas Janecke¹¹  | Vassiliki Konstantopoulou¹² | Dominic Lenz⁶  | Johannes A. Mayr³  | Thomas Müller¹¹ | Holger Prokisch^{1,2}  | Georg F. Vogel^{11,13} 

¹School of Medicine, Institute of Human Genetics, Technical University of Munich, Munich, Germany

²Institute of Neurogenomics, Computational Health Center, Helmholtz Zentrum München, Neuherberg, Germany

³University Children's Hospital, Salzburger Landeskliniken (SALK) and Paracelsus Medical University (PMU) Salzburg, Salzburg, Austria

⁴UCD School of Medicine & Medical Science, Crumlin, Dublin, Ireland

⁵Immundiagnostik AG, Bensheim, Germany

⁶Department I, Division of Pediatric Neurology and Metabolic Medicine Heidelberg University, Medical Faculty Heidelberg, Center for Pediatric and Adolescent Medicine, Heidelberg, Germany

⁷University of Heidelberg, Institute of Pathology, Heidelberg, Germany

⁸King's College Hospital, Paediatric Liver, GI & Nutrition Centre, London, United Kingdom

⁹Department of Paediatric Gastroenterology, Medical University of Vienna, Vienna, Austria

¹⁰Department of Paediatrics, Medical University of Vienna, Vienna, Austria

¹¹Department of Paediatrics I, Medical University of Innsbruck, Innsbruck, Austria

¹²Department of Paediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria

¹³Institute of Cell Biology, Medical University of Innsbruck, Innsbruck, Austria

Correspondence

Holger Prokisch, School of Medicine, Institute of Human Genetics Klinikum rechts der Isar, Technical University 81676 Munich, Germany. Email: holger.prokisch@helmholtz-munich.de

Georg-Friedrich Vogel, Department of Paediatrics I, Institute of Cell Biology, Medical University of Innsbruck 6020, Austria. Email: georg.vogel@i-med.ac.at

Abstract

Background: Pediatric acute liver failure (PALF) is a rare and life-threatening condition. In up to 50% of PALF cases, the underlying etiology remains unknown during routine clinical testing. This lack of knowledge complicates clinical management and liver transplantation decisions. Recently, whole-exome sequencing has identified genetic disorders in a large number of cases without specific laboratory biomarkers or metabolic fingerprints.

Abbreviations: ALF, acute liver failure; CADD, Combined Annotation Dependent Depletion; LT, liver transplantation; PALF, pediatric acute liver failure; PALFES, Pediatric Acute Liver Failure Exome Sequencing; TMT, tandem mass tag; TRPM7, transient receptor potential cation channel subfamily M member 7; WES, whole-exome sequencing.

Holger Prokisch and Georg F. Vogel contributed equally to this work.

Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's website, www.hepcommjournal.com.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.

Methods: We describe how further analysis of whole-exome sequencing data combined with proteomic analyses in 5 previously unsolved PALF patients, where no pathogenic variants in genes previously associated with acute liver failure were identified, revealed rare biallelic variants in transient receptor potential cation channel subfamily M member 7 (*TRPM7*).

Results: We establish *TRPM7* as a novel disease gene for PALF. Yet, the cation channel kinase *TRPM7* has not been associated with any Mendelian disorder. No homozygous loss-of-function variants were found in in-house exomes or publicly available databases. Rare biallelic *TRPM7*-variants were significantly enriched in the PALF cohort compared with a pediatric control cohort. Viral infections preceded the majority of PALF episodes. Recurrent PALF episodes characterized the disease course with rapid progression, leading to early death in 3 cases. Proteomic analyses of patient fibroblasts unveiled significantly reduced *TRPM7* protein levels, indicative of functional impairment. Severely reduced Mg^{2+} levels in one individual with a mutation in the channel domain suggests a potential interaction between disturbed Mg^{2+} homeostasis and PALF. The consistent presence of mutations in the *TRPM7* protein-kinase-domain across all patients suggests its specific relevance in PALF.

Conclusions: Our data extend the genetic spectrum of recurrent PALF and prompt consideration of *TRPM7* in children with unexplained liver failure.

Keywords: pediatric acute liver failure, *TRPM7*, whole-exome sequencing

INTRODUCTION

Pediatric acute liver failure (PALF) is a rare and life-threatening condition predominantly affecting children during their first years of life.^[1,2] It is characterized by high morbidity and mortality rates.^[3] Effective management of PALF requires the expertise of specialized pediatric centers with an interdisciplinary team. The spectrum of underlying etiologies primarily comprises intoxication, metabolic disorders, and viral infections.^[3,4] A timely diagnosis is of paramount importance, not only for the initiation of optimal treatment but also to allow prediction of the disease course. In the setting of recurrent episodes of acute liver failure (ALF), a molecular diagnosis can help to prevent additional PALF episodes and optimize care.

However, in both American and European cohorts, in approximately half of PALF cases the underlying etiology remains unknown after routine diagnostics. This uncertainty significantly complicates clinical management, hinders the implementation of disease-specific therapies, and poses challenges in decisions related to liver transplantation (LT).^[1,5–7]

In recent years, whole-exome sequencing (WES) has been established as a tool to search for genetic causes in undetermined PALF cases. Genetic disorders

have been identified in a large number of cases, particularly in those without specific laboratory biomarkers or metabolic fingerprints. WES revealed a higher impact of genetic disorders on PALF than previously thought.^[8,9] For example, in the international PALFES study, of 250 indeterminate PALF cases, WES identified a genetic basis in ~40% of cases.^[2]

We describe 5 children from 3 unrelated families with PALF who were found by WES to carry biallelic variants in transient receptor potential cation channel subfamily M member 7 (*TRPM7*). Functional studies in patient fibroblasts showed significantly reduced *TRPM7* protein levels, suggesting that deleterious variants in *TRPM7* are associated with PALF.

METHODS

Patient recruitment

All 5 pediatric patients were extracted from the Pediatric Acute Liver Failure Exome Sequencing (PALFES) study. PALFES is an international, multicenter observational study designed to investigate the genetic causes of indeterminate PALF.^[2] The study includes both prospective and retrospective cases, enrolling 260

patients aged 0–18 years from 19 countries between 2011 and 2022. Patients were included if no cause of PALF was identified after routine clinical workup, with both initial and recurrent presentations considered. WES was performed in all PALF cases to identify genetic etiologies, with a special focus on 243 genes previously reported to be associated with ALF. If no diagnosis was found within these genes, the entire exome was evaluated. Prior to study participation, informed consent was obtained from the patients and their parents in accordance with the local regulations. The study was conducted in accordance with both the Declaration of Helsinki^[10] and Istanbul and approved by the ethics committees of the participating centers where biological samples were collected. Written consent was given in writing by all subjects must be included within the methods section of the manuscript.

WES and variant prioritization

WES was performed at the Institute of Human Genetics, Klinikum rechts der Isar, Technische Universität

München (TUM, Munich, Germany). An in-house pipeline at TUM was used for the analysis of the WES data.^[11] WES was performed on blood-extracted genomic DNA as previously published.^[12] Sequencing reads were aligned to the human genome assembly GRCh37/hg19 (UCSC Genome Browser) using the Burrows-Wheeler Aligner (v.0.7.5a).^[13] Single nucleotide variants, as well as small insertions and deletions, were detected using the Genome Analysis Toolkit.^[14] Copy number variants were detected using ExomeDepth.^[15] Mitochondrial DNA variants were detected from exonic data as previously outlined.^[16]

Cell culture

Fibroblasts from family 1 (individuals 2 and 3) were collected postmortem, while fibroblasts from individual 5 were collected during the patient's lifetime. Primary patient-derived fibroblast cell lines were cultured in high glucose DMEM supplemented with supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, and 200 μ M uridine at 37 °C and 5% CO₂.




FIGURE 1 Family pedigrees and liver histopathology. (A) Pedigrees of 3 families identified with identified recessive inherited mutations in transient receptor potential cation channel subfamily M member 7 (*TRPM7*). (B) Hematoxylin-eosin staining of liver biopsies from individuals 3, 4, and 5 (I3, I4, and I5), showing micronodular cirrhosis, canalicular, and hepatocellular cholestasis in I3; parenchymal damage, bridging collapse, and severe cholestasis in I4; low hepatic damage and chronic cholestasis with portal and septal fibrosis in I5. The scale bar is 500 μ m.

RNA sequencing

RNA was isolated from patients' fibroblasts whole cell lysates using standard procedures.^[17] RNA integrity number was assessed using Agilent 2100 BioAnalyze. Strand-specific, polyA-enriched RNA sequencing was performed according to previously published protocols, and reads were aligned to the GRCh37/hg19 reference using the spliced transcripts alignment to a reference aligner.^[17] RNA sequencing data analysis was carried out using DROP,^[18] an integrative pipeline that integrates quality control and expression outlier calling with Outlier in RNA-Seq Finder.^[19]

Tandem mass tag–labeled quantitative proteomics

Quantitative tandem mass tag (TMT) proteomics analysis was performed at the BayBioMS Core Facility of the Technical University of Munich (Freising, Germany) on patient fibroblasts. Fibroblast cell pellets containing 0.5 million cells each were lysed under denaturing conditions in a buffer containing urea and quantified using the BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA). Protein extract (15 µg) was further reduced and alkylated, and the tryptic digestion was performed using Trypsin Gold (Promega, Madison, WI). Digests were acidified and desalted, and TMT-labeling was performed according to Zecha et al^[20] using the TMT 11-plex labeling reagent (Thermo Scientific, Waltham, MA). Each TMT batch consisted of 9 patient samples and 2 reference samples. The TMT 11-plex peptide mixture was fractionated using trimodal mixed-mode chromatography, according to Yu et al.^[21] LC-MS measurements were performed on a Fusion Lumos Tribrid mass spectrometer (Thermo Scientific) in the data-dependent acquisition mode and multinotch MS3 mode. Peptide identification was performed using MaxQuant (version 1.6.3.4),^[22] resulting in the identification of protein groups. Protein group intensities were then normalized to account for variability within and between TMT batches. Protein expression outlier identification was performed by comparing normalized protein intensities of the 3 case samples to those of 18 controls of the same batch using the Wilcoxon test approach. All statistical analyses were performed using R version 4.0.4.

RESULTS

As part of the PALFES study, we performed WES in 3 unrelated families from Syria, Ireland, and Germany but did not identify any pathogenic or likely pathogenic variants in genes previously associated with ALF.^[2] Instead, we identified biallelic variants in *TRPM7* within

these families, establishing *TRPM7* as a novel disease gene for PALF (Figure 1).

Individual 1 is the eldest of the 3 affected brothers in family 1 (including individuals 2 and 3, Figure 1). Two of the 3 presented with recurrent episodes of ALF starting at 6 and 7 months of age. These episodes were always associated with viral infections of the upper respiratory tract (Table 1, Figure 2). Treatment during ALF episodes was symptomatic. For individual 3, a high-urgency LT was opted. All 3 children passed away due to ALF at the ages of 37, 42, and 9 months without receiving LT.

Individual 4 from family 2 presented with episodes of ALF at the age of 9 and 15 months, along with encephalopathy during intercurrent viral illness that required intubation and ventilation (Table 1, Figure 2). Both episodes settled on conservative treatment. At the age of 19 months, she presented again with ALF and encephalopathy following a 2-day history of vomiting illness. The patient subsequently underwent a liver transplantation. At the most recent follow-up, the patient was 17 years old and in good health with standard immune suppression (tacrolimus, mycophenolate, and prednisolone).

Individual 5 from family 3 presented with ALF episodes at the age of 35 and 40 months (Table 1, Figure 2). An influenza A virus infection was detected during the first episode. After almost complete recovery from the first episode of ALF, the second episode, preceded by respiratory adenovirus infection, was noted 5 months later (Supplemental Table S1, <http://links.lww.com/HC9/B152>). Management was symptomatic for the first episode and included plasmapheresis, as well as N-acetylcysteine and magnesium substitution during the second episode. Both episodes were resolved. The patient was diagnosed with a urachal cyst that required surgical removal. During the latest follow-up examination at the age of 4 years, the patient was in good health. His AST/ALT levels were slightly above the normal limit, and synthetic liver function was normal. He is currently treated with ursodeoxycholic acid and receives vitamin K and vitamin D supplementation, as well as potassium and magnesium.

A concise summary of the clinical findings is given in Table 1.

In summary, the first episodes of ALF were recorded at a median age of 9 months (IQR: 28) with a median of 2 (IQR: 2) episodes of ALF per individual. Time to International normalized ratio recovery after episodes of ALF was a median of 12 days (range 4–28 d, IQR: 5.5) (Supplemental Table S2, <http://links.lww.com/HC9/B153>). Liver enzyme tests revealed elevated levels of ALT and AST (ALT: median 1.070 U/L, IQR 6.081; AST: median 3.465 U/L, IQR 20.049), lactate dehydrogenase (median 5.309.5 U/L, IQR 10.833 U/L), total and direct bilirubin (median 103.36 µmol/L, IQR: 120.66; direct bilirubin: median 56.01 µmol/L, IQR 117.3), GGT

TABLE 1 Clinical characteristics of the patient cohort.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Sex	Male	Male	Male	Female	Male
Alive	No	No	No	Yes	Yes
Age last follow-up (mo)	37	42	9	212	42
Pregnancy	Unremarkable	Unremarkable	Unremarkable	Unremarkable	Unremarkable
Anthropometry at birth	Unremarkable	Unremarkable	Unremarkable	Unremarkable	Unremarkable
TRPM7 variant 1	c.4955C > T; p. Pro1652Leu	c.4955C > T; p. Pro1652Leu	c.4955C > T; p. Pro1652Leu	c.[2005_2006del]; p. [Ser699Ter]	c.[553G > T]; p. [Gly185Ter]
TRPM7 variant 2	c.4955C > T; p. Pro1652Leu	c.4955C > T; p. Pro1652Leu	c.4955C > T; p. Pro1652Leu	c. [5329G > A]; p. [Asp1777Asn]	c.[5475G > T]; p. [Lys1825Asn]
Hepatic symptoms					
Age at first symptoms (mo)	36	6	7	9	35
ALF episodes	1	4	2	3	2
HE	Yes	Yes	Yes	Yes	Yes
trigger of ALF	Viral infection	Viral infection	Viral infection	NA	Viral infection
TB (μmol/L)	37.57	94.52	467.16	NA	112.2
DB (μmol/L)	30.43	24.65	340.34	NA	81.6
ASAT (IU/L)	25,318	21,000	178	951	3465
ALAT (IU/L)	7435	6800	100	719	1070
GGT (IU/L)	n.a.	154	45	NA	1730
LDH (IU/L)	14,600	10,167	413	NA	452
INR	> 6	> 6	> 6	> 6	1.57
Albumin (g/L)	NA	NA	26359	NA	25.9
Ammonia (μmol/L)	144	366	165	NA	67
Mg (mmol/L)	Normal	Normal	Normal	Normal	0.3
Liver transplantation	No	No	Listed	Yes	No
age at LT (mo)	NA	NA	NA	68	NA
Clinical course	Deceased during ALF	Deceased during ALF	Deceased during ALF	Unremarkable after LT	Recovered from ALF
Other organ manifestations	No	No	No	No	No

Abbreviations: ALF, acute liver failure; DB, direct bilirubin; INR, international normalized ratio; LDH, lactate dehydrogenase; LT, liver transplantation; NA, not available; TB, total bilirubin.

(median 154 U/L, IQR: 842.5). International normalized ratio was > 6 in individuals 1–4 and 1.57 in individual 5.

All patients presented with HE. Ammonia levels were elevated in all patients, with a median of 150.0 μmol/L (IQR: 21). Serum magnesium levels were within the normal range for individuals 1–4 but decreased in individual 5, who showed chronic hypomagnesemia even under oral substitution (0.3 mmol/L, expected 0.7–0.95 mmol/L).

Evaluation for inborn errors of metabolism, hepatotropic infections (except for 2 episodes of ALF) or intoxication was negative in all cases (Supplemental Table S2, <http://links.lww.com/HC9/B153>). Viral infections of the upper respiratory tract were identified as triggers for all but 2 ALF episodes (10/12, 2 NA) (Supplemental Table S1, <http://links.lww.com/HC9/B152>).

Treatment was primarily symptomatic. Plasmapheresis as well as administration of N-acetylcysteine and magnesium were reported for individual 5. Three of the 5 patients died due to ALF (individuals 1–3, family 1). Individual 4 underwent LT during the second ALF episode at the age of 19 months. Individual 5 is alive with his native liver.

Liver biopsy and histopathological evaluation were performed in all except individual 2, and histology revealed varying degrees of parenchymal damage or hepatocyte steatosis with no features common to all patients (Table 2, Figure 1). Of note, no CD8-positive T-cell infiltrates were found.

Pregnancy and birth were unremarkable in all patients. No overt extrahepatic manifestations were reported in individuals 1–4. In individual 5, growth retardation and a ventricle septum defect were reported




FIGURE 2 The occurrence of acute liver failure episodes for each patient depicted as density plot. The occurrence of acute liver failure episodes is indicated by curves. The age of death of individuals is indicated by dashed lines. Individuals 1, 2, and 3 are from family 1 (green).

(Table 1). Dysmorphism or inborn mental retardation was not reported in any of the 5 individuals during the follow-up period.

As no variants explaining the ALF phenotype were identified in any of the 5 affected individuals in the PALFES study, a genome-wide search for rare potential biallelic variants (allele frequency < 0.001) with predicted deleterious effects (Combined Annotation Dependent Depletion [CADD] score > 20) was conducted in all 3 families. In all 5 affected individuals, potential biallelic variants were identified in *TRPM7*, a gene so far not associated with a Mendelian disorder (Figure 1A). In family 1, only 1 homozygous missense variant (c.[4955C > T]; p.[Pro1652Leu]) was identified in all 3 affected individuals (Figure 3). The 3 affected siblings did not share any other rare biallelic variants with a CADD score of ≥ 20 . Remarkably, this homozygous *TRPM7* missense variant appears to be a founder mutation situated within a broader genomic region (≥ 20 Mb), where the affected individuals share an identical haplotype. The search for rare potential biallelic variants (allele frequency < 0.001) with predicted deleterious effects (CADD score > 20) in the affected individuals from families 2 and 3 also only revealed compound heterozygous variants in *TRPM7* and no other rare biallelic variants. Each of them presents a distinctive combination of a missense and a loss-of-function variant (Figure 3).

Next, to determine whether rare biallelic variants in *TRPM7* are frequent in the population, all 30,000 in-house WES cases were searched by applying the same filters as for the unsolved ALF cases. Only 1 additional case with rare potential biallelic variants and a CADD score of > 20 in *TRPM7* was discovered in our database of 30,000 WES cases. Notably, this particular case has already been resolved with another genetic

diagnosis, as the patient carried a homozygous variant in the *GBE1* gene. Thus, we found a significant enrichment of rare biallelic *TRPM7* variants in 150 unsolved PALF cases compared to the WES data from individuals without ALF ($p \leq 0.0001$, Fisher exact test).

To elucidate the consequences of the *TRPM7* variants, functional analyses of primary patient-derived fibroblasts were performed. These analyses included fibroblasts from individuals 2 and 3 with the homozygous *TRPM7* c.[4955C > T] p.[Pro1652Leu] variant. Additionally, fibroblasts from individual 5, who carries compound heterozygous variants in *TRPM7* (c.[553G > T];[5475G > T], p.[Gly185Ter];[Lys1825Asn]), were analyzed. Proteomic analyses showed a significant and specific decrease in *TRPM7* protein levels in fibroblasts from all 3 affected individuals compared to 18 control fibroblasts (Figure 4). The reduced *TRPM7* protein level supports the deleterious character of the rare biallelic variants identified in *TRPM7*. Notably, there were differences in *TRPM7* protein levels between family 1 and family 3. Yet all 3 children in family 1 died due to ALF within the first 4 years of life, while individual 5 was in good condition at the age of 4.

DISCUSSION

In summary, we describe 3 unrelated families with PALF carrying biallelic variants in *TRPM7* and provide convincing evidence that deleterious variants in *TRPM7* are associated with PALF. We identified a homozygous *TRPM7* variant in all 3 affected PALF family members and biallelic variants in 2 further families with PALF. Rare biallelic potentially damaging variants were significantly enriched in PALF cases versus controls and all affected individuals share the phenotype of mostly

TABLE 2 Histopathologic characteristics of the patient cohort

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Liver histology	Microvesicular steatosis, centro-lobular necrosis, portal fields, and bile ducts regular, no signs of cholestasis, no signs of inflammation	NA	Micronodular cirrhosis, canalicular and hepatocellular cholestasis, lack of steatosis	Severe parenchymal damage, bridging collapse, and severe cholestasis. Steatosis maximal in regenerative nodules, few multinucleate giant cells	Low hepatic damage, low bilirubinostasis, low chronic cholestasis signs, signs of clearance reaction and regeneration, portal/septal fibrosis, signs of ER activation, lack of steatosis.

Abbreviations: ER, endoplasmic reticulum; NA, not available.

recurrent ALF episodes. Finally, proteomics analyses further supported the deleterious effects of the identified variants in *TRPM7*.

The *TRPM7* gene, located on chromosome 15, is 129.64 kb in size and consists of 39 exons that encode a protein of 1865 amino acids (Figure 3). *TRPM7* is a divalent cation channel that is highly selective for Mg^{2+} , Zn^{2+} , and Ca^{2+} . It is involved in the maintenance of cellular and organismal bivalent cation homeostasis and is regulated by intracellular Mg^{2+} nucleotide levels, PIP2, and mechanical cues.^[23–25] The transient receptor potential melastatin family is a group of cell membrane cation channels consisting of 8 members, including the transient receptor potential cation channel subfamily M member 7 (*TRPM7*) [MIM:605692].^[26,27] It is a plasma membrane protein with a dual function consisting of a transient receptor potential ion channel fused to a protein kinase domain^[28,29] (Figure 5). In order to form a channel pore, *TRPM7* is presumed to form a tetrameric complex consisting of 4 *TRPM7* monomers, which have a high permeability to bivalent cations.^[32,33] In contrast to the relatively tissue-specific expression of the other 7 members of the transient receptor potential melastatin subfamily, the *TRPM7* channel kinase is ubiquitously expressed.^[34,35]

The importance of *TRPM7* in developmental processes and cell viability has been demonstrated in several studies. The germline deletion of *TRPM7* in mice resulted in embryonic lethality, with death occurring prior to embryonic day 7.5.^[25,36,37] The essential character of *TRPM7* in humans is supported by the absence of homozygous loss-of-function variants in public databases. So far, *TRPM7* has not been linked to Mendelian diseases in the OMIM database.^[38]

In agreement with the predicted essential function of *TRPM7*, all patients carry at least 1 missense variant. All missense variants identified in our study are localized within the C-terminal α -kinase domain of the *TRPM7* protein. All other variants are loss-of-function variants. In all PALF cases, this results in the sole expression of *TRPM7* proteins with a missense variant in the α -kinase domain but otherwise functional channel domains, indicating a regulatory deficiency of *TRPM7* function (Figure 3).

In 2020, rare heterozygous missense variants affecting the transmembrane region of *TRPM7* were found in a population of unexplained stillbirth. It was hypothesized that the variants could affect ion channel function and potentially cause lethal arrhythmias in utero.^[39] In another study, heterozygous missense variants in the transmembrane segment have been suggested to result in impaired ion channel function and thus may cause recurrent hemoplegic migraine attacks accompanied by intractable hypomagnesemia.^[40]

In 2022, biallelic variants in *TRPM6*, which has a high level of homology with *TRPM7*, were identified to be causative for hypomagnesemia and secondary




FIGURE 3 Transient receptor potential cation channel subfamily M member 7 (*TRPM7*) variants and gene structure. Genomic organization of *TRPM7* depicting the localization and phylogenetic conservation of amino acid residues affected by mutations identified in the 3 families. Positions of mutations are highlighted in red. All altered sites demonstrate high evolutionary conservation across diverse species, underscoring their functional significance. The variants were absent in the gnomAD database, as well as in over 30,000 in-house exomes. Based on in silico prediction tools, all 5 distinct variants had a CADD score above 24, supporting their deleterious effect. Regions are not drawn to scale. Abbreviations: CADD, Combined Annotation Dependent Depletion; TRP, transient receptor potential.

hypocalcemia.^[41,42] Vargas-Poussou et al^[43] presented *TRPM7* as a candidate gene for autosomal dominant hypomagnesemia and secondary hypocalcemia. Interestingly, Mg^{2+} levels were normal in all of our patients except for individual 5, who had severe hypomagnesemia during ALF episodes and showed chronic hypomagnesemia even under oral substitution. Therefore, we consider it unlikely that a generalized disruption of Mg^{2+} homeostasis is causative for ALF but suggest that

a regulatory dysfunction of *TRPM7* in the liver is responsible for PALF, consistent with the role of *TRPM7* in intestinal magnesium reabsorption.^[25,44]

Surprisingly, in a recent publication, a biallelic frameshift variant in the transmembrane segment of *TRPM7* was reported in 2 siblings with Hallermann-Streiff syndrome [MIM:234100] in a highly consanguineous Pakistani family, characterized by craniofacial dysmorphism.^[45,46] The frameshift variant was predicted to cause complete loss of *TRPM7* protein, but this was not validated. The absence of ALF in the 2 children aged 7 and 10 years could be by chance or suggest a gain of function of the identified missense variants in the *TRPM7* kinase domain in individuals with PALF. The gain of function in the ubiquitously expressed *TRPM7* may provide an explanation for the liver-specific phenotype. Further studies are needed to understand the pathomechanism leading to ALF. Fibroblast cell lines are likely not the best model system, nor is the embryonic lethal *TRPM7* knockout mouse model, suggesting modeling of the identified variants or taking advantage of hepatic model systems.

Benign viral infections preceded 83%, 2 of 10 potentially hepatotropic, of the PALF episodes in this cohort. It seems that hepatic homeostasis of the 5 patients reported is easily affected by viral infections. This might implicate a potential role of *TRPM7* in cellular stress responses, such as the unfolded protein response. This has been demonstrated in neurons with *TRPM7* overexpression.^[47] Similarly, patients with Wolcott-Rallison syndrome, which affects the unfolded




FIGURE 4 The rare biallelic variants in *TRPM7* result in significantly reduced *TRPM7* protein level in fibroblasts. *TRPM7* protein z-score distribution in 3 cases and 18 control cell lines. Cases include individuals 2 and 3 of family 1 and individual 5 of family 3. Controls are pediatric fibroblasts from patients with no rare variants in *TRPM7*. Abbreviation: *TRPM7*, transient receptor potential cation channel subfamily M member 7.




FIGURE 5 TRPM7 protein structure. The protein comprises 4 melastatin homologous regions in the N-terminal domain and 6 transmembrane segments with a pore region located between segments 5 and 6. The C-terminal domain consists of the transient receptor potential region, followed by the connecting loop of the coiled-coil domain and the serine/threonine protein kinase domain, which is able to phosphorylate substrates and regulate the activity of downstream target proteins.^[30,31] Abbreviations: MHR, melastatin homologous regions; TRP, transient receptor potential.

protein response, are prone to PALF during episodes of viral infection.^[48]

In conclusion, we provided statistical evidence and functional data supporting TRPM7 as a cause of PALF, thereby expanding the clinical and mutational spectrum of the disease. We reported pathogenic variants in TRPM7 in 3 unrelated families. Further families and cases are needed to better understand the genotype-phenotype correlation and underlying pathomechanism. Based on the clinical presentation and course of the 5 reported individuals, we can deduce that timely and specialized care for PALF is of paramount importance. While PALF episodes may resolve in these children, the presence of hepatic encephalopathy requires consideration of LT. This is further supported by the absence of neurocognitive impairment in patients with *TRPM7* variants in our cohort, including individual 4 aged 17 years with LT at the age of 19 months.

AUTHOR CONTRIBUTIONS

Lea D. Schlieben, Johannes A. Mayr, Holger Prokisch, and Georg F. Vogel were responsible for the conception and design of this study. Lea D. Schlieben interpreted the genetic and proteomic results and was responsible for the statistical analysis and data visualization. Holger Prokisch and Georg F. Vogel supervised the study.

FUNDING INFORMATION

This study was supported by the BMBF (German Federal Ministry of Education and Research) through the mitoNET German Network for Mitochondrial Diseases (grant number 01GM1906B) and the EJP RD

project GENOMIT (grant numbers 01GM1207 and 16478-B financed by the Austrian Science Fund FWF).

ACKNOWLEDGMENTS

The authors thank the families for the collaboration.

CONFLICTS OF INTEREST

Max Diesner is employed by Immundiagnostik AG. Vassiliki Konstantopoulou consults, advises, and received grants from Chiesi. He consults and advises Amicus. He is on the speakers' bureau for Sanofi and Takeda. He received grants from Nutricia Metabolics and Biomarin. The remaining authors have no conflicts to report.

ORCID

Lea D. Schlieben  <https://orcid.org/0000-0001-6583-256X>

René G. Feichtinger  <https://orcid.org/0000-0002-4215-8258>

Robert Hegarty  <https://orcid.org/0000-0002-5893-6464>

Andreas Janecke  <https://orcid.org/0000-0001-7155-0315>

Dominic Lenz  <https://orcid.org/0000-0002-9561-8190>

Johannes A. Mayr  <https://orcid.org/0000-0001-6970-336X>

Holger Prokisch  <https://orcid.org/0000-0003-2379-6286>

Georg F. Vogel  <https://orcid.org/0000-0002-2515-4490>

REFERENCES

- Squires RH, Shneider BL, Bucuvalas J, Alonso E, Sokol RJ, Narkewicz MR, et al. Acute liver failure in children: The first 348 patients in the pediatric acute liver failure study group. *J Pediatr*. 2006;148:652–58.e2.
- Lenz D, Schlieben LD, Shimura M, Bianzano A, Smirnov D, Kopajtich R, et al. Genetic landscape of pediatric acute liver failure of indeterminate origin. *Hepatology*. 2024;79:1075–87.
- Squires JE, Alonso EM, Ibrahim SH, Kasper V, Kehar M, Martinez M, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the diagnosis and management of pediatric acute liver failure. *J Pediatr Gastroenterol Nutr*. 2022;74:138–58.
- Lenz D, Hørby Jørgensen M, Kelly D, Cardinale V, Geerts A, Gonçalves Costa I, et al. Etiology and outcome of adult and pediatric acute liver failure in Europe. *J Pediatr Gastroenterol Nutr*. 2023;77:115–20.
- Squires JE, Alonso EM. Response to: comment on the “NASPGHAN Position Paper on the Diagnosis and Management of Pediatric Acute Liver Failure.”. *J Pediatr Gastroenterol Nutr*. 2022;74:e130–1.
- Kathemann S, Bechmann LP, Sowa J-P, Manka P, Dechêne A, Gerner P, et al. Etiology, outcome and prognostic factors of childhood acute liver failure in a German Single Center. *Annals of Hepatology*. 2015;14:722–8.
- Hegarty R, Hadzic N, Gissen P, Dhawan A. Inherited metabolic disorders presenting as acute liver failure in newborns and young children: King’s College Hospital experience. *Eur J Pediatr*. 2015;174:1387–92.
- Haack TB, Stauffer C, Köpke MG, Straub BK, Kölker S, Thiel C, et al. Biallelic mutations in NBAS cause recurrent acute liver failure with onset in infancy. *The American Journal of Human Genetics*. 2015;97:163–9.
- Hegarty R, Gibson P, Sambrotta M, Strautnieks S, Foskett P, Ellard S, et al. Study of acute liver failure in children using next generation sequencing technology. *J Pediatr*. 2021;236:124–30.
- World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. *JAMA*. 2013;310:2191–4.
- Riccardo Berutti, Schwarzmayr T, Strom TM. Exome Variant Annotation Database 2022.
- Zech M, Jech R, Boesch S, Škorvánek M, Weber S, Wagner M, et al. Monogenic variants in dystonia: An exome-wide sequencing study. *The Lancet Neurology*. 2020;19:908–18.
- Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. *Bioinformatics*. 2009;25:1754–60.
- Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, del Angel G, Levy-Moonshine A, et al. From FastQ data to high-confidence variant calls: The genome analysis toolkit best practices pipeline. *Current Protocols in Bioinformatics*. 2013;43:11.
- Plagnol V, Curtis J, Epstein M, Mok KY, Stebbings E, Grigoriadou S, et al. A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. *Bioinformatics*. 2012;28:2747–54.
- Wagner M, Berutti R, Lorenz-Depiereux B, Graf E, Eckstein G, Mayr JA, et al. Mitochondrial DNA mutation analysis from exome sequencing—A more holistic approach in diagnostics of suspected mitochondrial disease. *J Inherit Metab Dis*. 2019;42:909–17.
- Kremer LS, Bader DM, Mertes C, Kopajtich R, Pichler G, Iuso A, et al. Genetic diagnosis of Mendelian disorders via RNA sequencing. *Nat Commun*. 2017;8:15824.
- Yépez VA, Mertes C, Müller MF, Klaproth-Andrade D, Wachutka L, Frésard L, et al. Detection of aberrant gene expression events in RNA sequencing data. *Nat Protoc*. 2021;16:1276–96.
- Brechtmann F, Mertes C, Matusėvičiūtė A, Yépez VA, Avsec Ž, Herzog M, et al. OUTRIDER: A statistical method for detecting aberrantly expressed genes in RNA sequencing data. *Am J Hum Genet*. 2018;103:907–17.
- Zecha J, Satpathy S, Kanashova T, Avanesian SC, Kane MH, Clauser KR, et al. TMT labeling for the masses: A robust and cost-efficient, in-solution labeling approach. *Mol Cell Proteomics*. 2019;18:1468–78.
- Yu P, Petzoldt S, Wilhelm M, Zolg DP, Zheng R, Sun X, et al. Trimodal mixed mode chromatography that enables efficient offline two-dimensional peptide fractionation for proteome analysis. *Anal Chem*. 2017;89:8884–91.
- Tyanova S, Temu T, Cox J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. *Nat Protoc*. 2016;11:2301–19.
- Paravicini TM, Chubanov V, Gudermann T. TRPM7: A unique channel involved in magnesium homeostasis. *The International Journal of Biochemistry & Cell Biology*. 2012;44:1381–4.
- Monteilh-Zoller MK, Hermosura MC, Nadler MJS, Scharenberg AM, Penner R, Fleig A. TRPM7 provides an ion channel mechanism for cellular entry of trace metal ions. *J Gen Physiol*. 2003;121:49–60.
- Mittermeier L, Demirkhanyan L, Stadlbauer B, Breit A, Recordati C, Hilgendorff A, et al. TRPM7 is the central gatekeeper of intestinal mineral absorption essential for postnatal survival. *Proc Natl Acad Sci USA*. 2019;116:4706–15.
- Montell C. The TRP superfamily of cation channels. *Science’s STKE*. 2005;2005:re3–.
- Runnels LW, Yue L, Clapham DE. TRP-PLIK, a bifunctional protein with kinase and ion channel activities. *Science*. 2001;291:1043–7.
- Nadler MJS, Hermosura MC, Inabe K, Perraud A-L, Zhu Q, Stokes AJ, et al. LTRPC7 is a Mg-ATP-regulated divalent cation channel required for cell viability. *Nature*. 2001;411:590–5.
- Runnels LW. TRPM6 and TRPM7: A Mul-TRP-PLIK-cation of channel functions. *CPB*. 2011;12:42–53.
- Zou Z-G, Rios FJ, Montezano AC, Touyz RM. TRPM7, magnesium, and signaling. *IJMS*. 2019;20:1877.
- Yee N, Kazi A, Yee R. Cellular and developmental biology of TRPM7 channel-kinase: Implicated roles in cancer. *Cells*. 2014;3:751–77.
- Nadolni W, Zierler S. The channel-kinase TRPM7 as novel regulator of immune system homeostasis. *Cells*. 2018;7:109.
- Visser D, Middelbeek J, Van Leeuwen FN, Jalink K. Function and regulation of the channel-kinase TRPM7 in health and disease. *Eur J Cell Biol*. 2014;93:455–65.
- Fonfria E, Murdock PR, Cusdin FS, Benham CD, Kelsell RE, McNulty S. Tissue distribution profiles of the human TRPM cation channel family. *Journal of Receptors and Signal Transduction*. 2006;26:159–78.
- Kunert-Keil C, Bisping F, Krüger J, Brinkmeier H. Tissue-specific expression of TRP channel genes in the mouse and its variation in three different mouse strains. *BMC Genomics*. 2006;7:159.
- Jin J, Desai BN, Navarro B, Donovan A, Andrews NC, Clapham DE. Deletion of *Trpm7* disrupts embryonic development and thymopoiesis without altering Mg²⁺ homeostasis. *Science*. 2008;322:756–60.
- Jin J, Wu L-J, Jun J, Cheng X, Xu H, Andrews NC, et al. The channel kinase, *TRPM7*, is required for early embryonic development. *Proc Natl Acad Sci USA*. 2012;109:E225–33.
- McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD). Online Mendelian Inheritance in Man, OMIM 2024.
- Cartwright JH, Aziz Q, Harmer SC, Thayyil S, Tinker A, Munroe PB. Genetic variants in TRPM7 associated with unexplained stillbirth modify ion channel function. *Hum Mol Genet*. 2020;29:1797–807.

40. Lei M, Wang P, Li H, Liu X, Shu J, Zhang Q, et al. Case report: Recurrent hemiplegic migraine attacks accompanied by intractable hypomagnesemia due to a de novo TRPM7 gene variant. *Front Pediatr.* 2022;10:880242.
41. Walder RY, Landau D, Meyer P, Shalev H, Tsolia M, Borochowitz Z, et al. Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. *Nat Genet.* 2002;31:171–4.
42. Lainez S, Schlingmann KP, Van Der Wijst J, Dworniczak B, Van Zeeland F, Konrad M, et al. New TRPM6 missense mutations linked to hypomagnesemia with secondary hypocalcemia. *Eur J Hum Genet.* 2014;22:497–504.
43. Vargas-Poussou R, Claverie-Martin F, Prot-Bertoye C, Carotti V, Van Der Wijst J, Perdomo-Ramirez A, et al. Possible role for rare *TRPM7* variants in patients with hypomagnesaemia with secondary hypocalcaemia. *Nephrol Dial Transplant.* 2023;38:679–90.
44. Schmidt E, Narangoda C, Nörenberg W, Egawa M, Rössig A, Leonhardt M, et al. Structural mechanism of TRPM7 channel regulation by intracellular magnesium. *Cell Mol Life Sci.* 2022;79:225.
45. Preudhomme R, Veyssiere A, Ambroise B, Benateau H. Hallermann Streiff syndrome: Cranio-facial manifestations systematic review and report of two cases. *J Stomatol Oral Maxillofac Surg.* 2022;123:e219–23.
46. Mudassir BU, Agha Z. Novel biallelic frameshift in TRPM7 gene causes Hallermann–Streiff syndrome in a consanguineous family: A case report. *Acta Neurol Belg.* 2024;124:321–4.
47. Huang Y, Leng T-D, Inoue K, Yang T, Liu M, Horgen FD, et al. TRPM7 channels play a role in high glucose–induced endoplasmic reticulum stress and neuronal cell apoptosis. *J. Biol. Chem.* 2018;293:14393–406.
48. Aldrian D, Bochdansky C, Kavallar AM, Mayerhofer C, Deeb A, Habeb A, et al. Natural history of Wolcott-Rallison syndrome: A systematic review and follow-up study. *Liver Int.* 2024;liv:15834.

How to cite this article: Schlieben LD, Achleitner MT, Bourke B, Diesner M, Feichtinger RG, Fichtner A, et al. Missense variants in the TRPM7 α -kinase domain are associated with recurrent pediatric acute liver failure. *Hepatol Commun.* 2024;8:e0598. <https://doi.org/10.1097/HCG9.0000000000000598>